• MM&M Facebook
  • MM&M Twitter
  • MM&M LinkedIn
  • MM&M Youtube
Advertise
Subscribe
Log in | Register
Medical Marketing & Media
  • News
    • Agencies
    • Data/Analytics
    • Campaigns
    • Commercial
    • Corporate
    • Legal/Regulatory
    • Media
    • Payers
    • Pipeline
    • Technology
    DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

    DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

    Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?

    Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

    Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

    Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

    DTC ads 2017: The good, the bad, and the ugly

    DTC ads 2017: The good, the bad, and the ugly

    We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.

  • Series
    • Data Week
    • Top 100 Agencies
    • Live at Cannes
    • Pharma Report
    • The DTC Report
    • Top 40 Transformers
    Profiles in Creativity

    Profiles in Creativity

    This six-part series, produced by the MM&M Content Lab in partnership with Klick Health, tells personal stories of people using creativity to solve problems in healthcare.

  • Events
    • Live Events
    • Webcasts
    • Leadership Exchanges
  • Videos
  • Resources
    • eBooks
    • Podcasts
    • The Agency Gallery
    • The PMD
    • Whitepapers
  • Careers
    • Women in Healthcare Marketing
    • People Moves
    • Career & Salary Survey Premium
  • Magazine
    • Latest Issue
    • Issue Archive
  • MM&M >
  • Newsletters >
  • MM&M KOL White Paper >
  • 2012

MM&M KOL White Paper

Choose another year:  2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
  • 11/15/12 - SK&A
  • 9/19/12 - SK&A
  • 9/19/12 TrialCard
  • 081612 Trialcard
  • 8/1/12 - Trialcard
  • 7/18/12 - SK&A
  • 6/26/12 - HRM
  • 5/16/12 - SK&A
  • TEST Roundup
  • 4/26/12 - eyeforpharma
  • 3/21/12 - WP Roundup
  • 3.14.12 - SK&A
  • 2/14/12 - EyeForPharma
  • 2/13/12 - WP Roundup
  • 1/18/12
  • 1/14/11 Whitepaper Roundup

Newsletters

Opinion

The cost of curing blindness: Navigating challenges on the road toward curative treatment

By Carolyn Sobczyk, JPA Health Communications

Will the real patient advocate please stand up?

By Marc Iskowitz

The Cambridge Analytica mess: What does it mean for pharma?

By Richard Watson, VP of Marketing Intelligence, and David Ormesher, CEO, Closerlook

MM&M Articles

  • Popular
  • Emailed
  • Recent
  • Marian Salzman exits Havas PR for Philip Morris International
  • Five things for pharma marketers to know: Monday, April 16, 2018
  • Five things for pharma marketers to know: Friday, April 13, 2018
  • Sorrell exit could spell the end for WPP, analysts say
  • Five things for pharma marketers to know: Wednesday, April 18, 2018
  • ePharma: Novo Nordisk's lessons from a diabetes education campaign
  • DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?
  • PBMs, drugmakers face off over copay accumulators
  • ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.
  • DTC ads 2017: The good, the bad, and the ugly
  • Lessons learned going live on Facebook with a branded drug
  • Five things for pharma marketers to know: Friday, April 20, 2018
  • P&G: healthcare acquisition helps us stay on top of consumer 'megatrends'
  • Private-equity funds dominate marcomms M&A
  • Five things for pharma marketers to know: Thursday, April 19, 2018

Medical Marketing & Media Return To Top

News

  • Agencies
  • Campaigns
  • Commercial
  • Corporate
  • Legal/Regulatory
  • Media
  • Payers
  • Pipeline

Opinion

  • Back Talk
  • Beltway Insider
  • Editor's Desk
  • Partner Forum
  • Private View
  • Viewpoint

User Center

  • Subscribe
  • About us
  • Contact us
  • Media Information
  • Sitemap
  • OBA Ad ChoicesAd Choices

Connect With Us

  • Newsletters
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
Copyright © 2018 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions.